rediff.com
REAL-TIME QUOTE
Enter Company or MF
e.g. Tata motors, Reliance MF, 500570
JUBILANT LIFE SCIENCES LIMITED - Updates
Download announcement < Back
21 Mar 2017
Sub: Disclosure under Regulation 30(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended The Board of Directors of Jubilant Pharma Limited (&apos;JPL&apos;), a material wholly owned subsidiary of the Company in Singapore, has approved to negotiate a potential acquisition of a specialty pharma business in the United States using only internal accruals, , subject to due diligence, satisfactory agreements, etc. and its final approval. The proposed acquisition is a niche, profitable speciality pharma business with a strategic fit and is expected to provide competitive edge for JPL&apos;s existing business, if it materialises.
View all announcements for JUBILANT LIFE SCIENCES LIMITED Source: BSE India